Compare BWEN & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | LTRN |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 49.9M |
| IPO Year | N/A | 2020 |
| Metric | BWEN | LTRN |
|---|---|---|
| Price | $3.26 | $3.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 322.2K | 71.4K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $153,877,000.00 | N/A |
| Revenue This Year | $11.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $2.55 |
| 52 Week High | $3.59 | $6.12 |
| Indicator | BWEN | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 47.80 |
| Support Level | $2.92 | $3.72 |
| Resistance Level | $3.59 | $3.98 |
| Average True Range (ATR) | 0.26 | 0.27 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 71.10 | 48.72 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.